Research programme: peptide therapeutics - KeyBioscience

Drug Profile

Research programme: peptide therapeutics - KeyBioscience

Alternative Names: KBP 089; KBP-056

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator KeyBioScience
  • Class Peptides
  • Mechanism of Action Amylin receptor agonists; Calcitonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 08 Jun 2017 Peptide therapeutics licensed to Eli Lilly worldwide
  • 11 Nov 2016 Preclinical trials in Liver disorders in Denmark (SC)
  • 11 Nov 2016 Preclinical trials in Non-alcoholic steatohepatitis in Denmark (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top